(BPT) - We often talk about breast cancer as if it is one disease. “Yeah, she had breast cancer,” or “she had a lump removed.” Even, “she has breast cancer. She’s going through chemo.”
But all breast cancers may not be the same. And chances are good that unless you or someone you are close to has been impacted directly, you may not know that.
Most breast cancers are defined by the presence of certain cancer cell receptors – specifically, hormone receptors called estrogen and progesterone receptors and a protein called human epidermal growth factor 2 (HER2). Knowing which receptors are present helps a doctor choose a treatment that a cancer type is most likely to respond to.
About 10-15% of all breast cancers, however, have little to no presence of any of these three receptors. In fact, they’re so named: “triple-negative” (TNBC), for the absence of all three.
Triple-negative breast cancers tend to spread faster than other breast cancers, and because they don't have the hormone receptors or HER2 protein, there are fewer medicines that work against them. This makes TNBC more aggressive than other invasive breast cancers.
“It’s triple-negative breast cancer” is often a much different diagnosis than “it’s breast cancer.”
Younger Women and People of Color Are Most Likely to Receive a TNBC Diagnosis
TNBC can take an especially hard toll. It affects younger women, before many have even started thinking seriously about mammograms or screenings. It is more likely to be diagnosed in women under 40 than most other types of breast cancer, and it is more common in Black and Hispanic women. To add to this, because it’s aggressive, it can become very serious very quickly. Once it spreads, only about 12% of women with metastatic disease survive 5 years.
Treatment Options For TNBC Are Expanding
For women who are facing an advanced TNBC diagnosis, it’s important to talk to the doctor about treatment options. Most patients with advanced or metastatic disease (TNBC that has spread) will receive chemotherapy, but many will progress at some point – even if the chemotherapy works initially. Until recently, there have been no other options after chemotherapy stops working. That is changing.
Trodelvy® (sacituzumab govitecan-hziy) is a different kind of medicine, called an antibody-drug conjugate (ADC), that is approved for adults with second-line and later metastatic TNBC (after two or more prior treatments, including one for metastatic disease). Trodelvy is indicated for TNBC (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease. That means when chemotherapy stops working, people with metastatic TNBC have another option.
Please click to see Important Facts about Trodelvy, including Important Warning for low white blood cell count and diarrhea.
If you or someone you know has metastatic TNBC, speak with a doctor about potential therapies, including Trodelvy.
For more information, please visit https://www.trodelvy.com/.
IMPORTANT SAFETY INFORMATION
TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).
Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.
Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.
The most common side effects of TRODELVY include feeling tired or weak, hair loss, decreased red blood cell count, constipation, decreased appetite, rash, and stomach-area (abdominal) pain or discomfort.
These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
WHAT IS TRODELVY?
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
Please click to see Important Facts about Trodelvy, including Important Warning.
A message from Gilead Sciences.
TRODELVY and GILEAD are trademarks of Gilead Sciences, Inc., or its related companies. All other marks are the property of their respective owners.
© 2022 Gilead Sciences, Inc. All rights reserved. US-TROC-0085 09/22
Other items that may interest you
We have noticed you are using an ad blocking plugin in your browser.
The revenue we receive from our advertisers helps make this site possible. We request you whitelist our site.